Federal Circuit Partly Reverses In Ophthalmic Drug Patent Dispute

WASHINGTON, D.C. - Although a Texas federal judge erred in finding certain claims of a combination ophthalmic drug treatment patent not invalid, several generic drug makers failed to prove by clear and convincing evidence that an asserted claim of a related patent would have been obvious, the Federal Circuit U.S. Court of Appeals ruled May 1 (Allergan Inc. v. Sandoz Inc., et al., Nos. 2011-1619, -1620, -1635, -1639, Fed. Cir.).

Access this news story on lexis.com®